Moderna Announces Positive Interim Data From Phase 2/3 Study Of COVID-19 Vaccine In Young Children

(RTTNews) - Moderna Inc. (MRNA) announced positive interim data from the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the company's vaccine candidate against COVID-19, in children 6 to 11 years of Age.

(RTTNews) - Moderna Inc. (MRNA) announced positive interim data from the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the company's vaccine candidate against COVID-19, in children 6 to 11 years of Age.